A STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION TRIAL
ENGAGE AF-TIMI 48 was the largest and longest comparative NVAF study to date with a NOAC1
Study design1
Dosing strategy
ENGAGE AF-TIMI 48 prospectively allowed for dose reduction in patients with one or more clinical factors which put them at increased risk of bleeding on LIXIANA® both at randomisation and during the trial:1
- Renal impairment (CrCl 30 to 50 ml/min)
- Low body weight (≤60 kg/132 lbs)
- Concomitant use of P-gp inhibitors verapamil, dronedarone or quinidine
ENGAGE AF-TIMI 48: Studied NVAF patients you may see in your daily clinical practice
ENGAGE AF-TIMI 48 enrolled a high percentage of patients who also had comorbidities or other risk factors.1
Study Highlights
References
- Giugliano RP et al. NEJM 2013;369(22):2093–2104.
- Ruff CT et al. Am Heart J 2010;160:635–641.
- Medscape.com. CHADS2 score for stroke risk: Assessment in Atrial Fibrillation. Available at http://emedicine.medscape.com/article/2172597-overview. Last accessed: September 2014.
- Schulman S and Kearon C. J Thromb Haemost 2005;3(4):692–694.